uniQure, which develops gene therapies for the treatment of orphan diseases, announced terms for its IPO on Friday. The Amsterdam, Netherlands-based company plans to raise $64 million by offering 4.6 million shares at a price range of $13 to $15. At the midpoint of the proposed range, uniQure would command a market value of $235 million.
uniQure, which was founded in 1998 and booked $3 million in license and collaboration revenue for the 12 months ended September 30, 2013, plans to list on the NASDAQ under the symbol QURE. uniQure initially filed confidentially on November 8, 2013. Jefferies, Leerink Partners and Piper Jaffray are the joint bookrunners on the deal.
